AZ, Chi-Med in final stage clinical trial with cancer drug

AstraZeneca and Chi-Med said on Thursday they kicked off the third phase of clinical testing of their cancer drug.

AstraZeneca is to pay $5 million milestone – triggered by the launching of the rare kidney cancer drug – to Chi-Med, a China-based biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.

The main goal of the final study phase is to test savolitinib in c-MET-driven papillary renal cell carcinoma